Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim opens new biotechnology R&D centre in Germany
The company has invested €350m in the new research and development (R&D) centre, representing its largest single investment in the country to date. The new high-tech facility will
The company has invested €350m in the new research and development (R&D) centre, representing its largest single investment in the country to date. The new high-tech facility will
Known as DERMAdoctor Comfort + Joy Psoriasis Therapeutic Moisturizing Cream with 3% salicylic acid, the product will be introduced on the QVC network. The new cream will be
This partnership will focus on exploring joint venture (JV) opportunities for advancing a Phase II ready asset and the preclinical prodrug asset of BullFrog AI. The Phase II
Currently, the company has six fill finish lines in San Diego, US, that includes a new line which provides various configurations, such as vials, cartridges, and prefilled syringes.
A first-in-class, phosphate absorption inhibitor, Xphozah will be used to control serum phosphate in adults with chronic kidney disease (CKD) on dialysis and who had an insufficient response
This therapy helps to pace up the recovery of neutrophils (a subset of white blood cells) in the body and lower risk infection. Omisirge is intended for use
Sweden-based Abliva has announced that its drug candidate NV354 has been received orphan drug designation (ODD) from the US FDA Office of Orphan Products Development to treat mitochondrial
The multi-year strategic partnership will leverage latest molecular profiling approaches guiding patient selection and participation to accelerate precision medicine approaches across five of the therapeutic programmes of Flare.
The definitive agreement between the companies was initially signed in January this year. The total deal value at close is nearly $1.2bn in upfront consideration and contingent value
Co-led by global investors Insight Partners and M Ventures, the financing round has also seen participation from Gaingels and One Way Ventures. ImmuneBridge is developing allogeneic NK cell-based